Regencell Bioscience shares rise 14.06% intraday following Jiangxi's support for brain-computer interface research in neurological disorders and the company's focus on TCM for ADHD/ASD treatment.

martes, 2 de diciembre de 2025, 10:09 am ET1 min de lectura
RGC--
Regencell Bioscience surged 14.06% intraday trading, driven by Jiangxi province's December 2025 policy supporting brain-computer interface technology research for neurological and psychiatric disorders, aligning with the company's focus on traditional Chinese medicine (TCM) treatments for neurocognitive conditions such as ADHD and ASD.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios